In a multicohort study, abdominal pain was found to be common in patients with ulcerative colitis, regardless of whether they ...

anti-IL-7 Receptor Lusvertikimab in Ulcerative Colitis accepted for Oral Presentation and selected amongst the Top 10 oral ...

A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a UM ...

Developed by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...

The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum ...

Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...

Discover how β-ionone offers relief from ulcerative colitis by enhancing gut health, reducing inflammation, and restoring ...

Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...